Your time spent on this site
Danish Startup secures $1 Million to bring affordable and rapid snakebite diagnostics to market
VenomAid Diagnostics, a company dedicated to developing rapid diagnostic tests for snakebite envenoming, announced today that it has successfully raised $1 million in funding from a select group of private Business Angels and the philanthropic venture fund Good Ventures LLC.
We tackle one of the world’s most neglected tropical diseases
is on the WHO’s list of top prioritized neglected tropical diseases, because of the hundreds of thousands of cases of suffering, morbidity, and mortality it causes every single year.
We are on a mission
to enable best-in-class snakebite care worldwide, with the vision
of reducing the global burden of snakebites.
Read more about snakebite envenoming at minutestodie.com
Current diagnosis is time consuming
A crucial part of treating snakebite envenoming is to correctly diagnose the patient so that they can receive the specific antivenom that might save their life.
If time from bite to treatment exceeds 6 hours, the clinical burden increases drastically.
The current symptom-based diagnosis creates a delay between bite and treatment and when symptoms appear it may already be too late to effectively treat snakebite envenoming. This means unnecessarily many people die or become crippled for life.
The VenomAid Diagnostick is an affordable and sensitive test capable of providing a clinically relevant diagnostic result within minutes of loading either blood- or wound-swab sample onto the device.
By quickly detecting which snake bit you, the doctors can start early and correct treatment, saving costs, and more importantly, your life.
Meet the innovators
Co-founder & CSO
Jonas A. Jürgensen
Co-founder & CEO
Søren H. Dam
Co-founder & RA
Gina M. Ross
Pelle D. Knudsen
Andreas H. Laustsen
Co-founder & Board Member
Selma B. Belfakir
Industrial PhD student